Nirma acquires majority stake in Glenmark Life Sciences

Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals

Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs. 5,652 Cr

Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report

Manipal Hospitals Mukundapur launches advanced Neuro Biplane Cathlab

State-of-the-art facility brings next-generation imaging and minimally invasive neurointerventional capabilities to Eastern India

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26

Experts seek insurance coverage for stroke rehabilitation as recovery costs rise

Experts also underscored the growing role of technologies such as tele-neurorehabilitation, robotics, and AI-driven therapies in improving recovery outcomes

Budget 2026-27: Government to establish 5 regional medical hubs to boost medical tourism

Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub

A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave